
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
| Review | Status | Reviewer | Date | Notes |
|---|---|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. | ||
| clinical review | not_started | Awaiting clinician review; check the outpatient handling of severe hypertension and the five-visit titration schedule. | ||
| provenance review | not_started | NPS biography, timeline, death bulletin, and news release logged; the 2006 conference is known only through the NPS bulletin; the birth date is uncertain. | ||
| safe messaging review | not_started | The 1915 'racial characteristics' remark is flagged as sensitive and presented only with context; death recorded without graphic detail. |
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|---|---|---|
| 2026-05-11 Progress note 02 (C-CDA) | Urinalysis with microscopy | At diagnosis, then with a change in status | Not on file from the diagnostic workup, a deviation from the protocol. It screens for blood or casts that would point away from hypertensive nephrosclerosis. Today's ultrasound and the history fit hypertensive kidney disease, so no harm is evident. Corrective action: obtain it if albuminuria does not fall on treatment or kidney function changes unexpectedly |
| 2026-05-11 Progress note 02 (C-CDA) | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5; before referral decisions | Not calculated before the nephrology referral, a deviation from the protocol. The referral stood on other criteria (eGFR below 60 with severely increased albuminuria), so no harm resulted. Corrective action: calculate at the six-month review, once eGFR has settled on full therapy |
| 2026-10-26 Progress note 07 (C-CDA) | 25-hydroxyvitamin D | Once at baseline | Not drawn at diagnosis or with today's calcium, phosphate, and PTH, a deviation from the protocol. PTH is falling with normal calcium and phosphate, so no harm is evident. Corrective action: added to the next draw |
| Visit | Type | Item | Status | Detail |
|---|---|---|---|---|
| 2026-09-21 Progress note 06 (C-CDA) | Prevention | Colorectal cancer screening | Referred | No prior screening on record; he chose colonoscopy. Referral sent with a request for a polyethylene glycol preparation and no sodium phosphate preparation, because of his kidney disease; hold dapagliflozin and chlorthalidone on the preparation day |
| 2026-09-21 Progress note 06 (C-CDA) | Prevention | Prostate cancer screening | Ordered | Shared decision-making about benefits, false positives, and overdiagnosis, including the higher prostate cancer risk among Black men described in the USPSTF statement. He chose PSA testing; added to the October blood draw |
| 2026-09-21 Progress note 06 (C-CDA) | Prevention | Hepatitis C and HIV screening | Ordered | One-time screening offered to all adults in these age ranges, not based on any individual risk; no prior result on record; added to the October blood draw |
| Claim | Statement | Certainty |
|---|---|---|
| CLM-0009 | A 2006 historical clinicopathological conference at the University of Maryland School of Medicine reviewed his hospital record and concluded that he presented with malignant hypertension that caused kidney failure. | probable |
| Claim | Grade | Statement |
|---|---|---|
| CLM-0010 | D | A 1915 remark by Dr. Bastedo attributing the death partly to 'racial characteristics' was read by Washington's Chicago physician, Dr. George C. Hall, as implying syphilis; the hospital Wassermann test was negative, and the 2006 review did not support that explanation. |
None.
Every note in the record, with its type. All clinical content is synthetic.
| Date | Result | Value | Flag |
|---|---|---|---|
| 2026-05-04 | Bicarbonate (total CO2) | 21 mmol/L (low) | Low |
| 2026-05-04 | BUN | 34 mg/dL (high) | High |
| 2026-05-04 | Creatinine | 2.1 mg/dL (high) | High |
| 2026-05-04 | eGFR | 36 mL/min/1.73 m² (low) | Low |
| 2026-05-04 | Intact PTH | 92 pg/mL (high) | High |
| 2026-05-04 | Hemoglobin | 12.6 g/dL (low) | Low |
| 2026-05-04 | LDL cholesterol | 138 mg/dL (high) | High |
| 2026-05-04 | Urine albumin-creatinine ratio | 820 mg/g (high) | High |
| 2026-05-11 | BUN | 36 mg/dL (high) | High |
| 2026-05-11 | Creatinine | 2.2 mg/dL (high) | High |
| 2026-05-11 | eGFR | 34 mL/min/1.73 m² (low) | Low |
| 2026-06-01 | BUN | 38 mg/dL (high) | High |
| 2026-06-01 | Creatinine | 2.4 mg/dL (high) | High |
| 2026-06-01 | eGFR | 30 mL/min/1.73 m² (low) | Low |
| 2026-06-29 | BUN | 36 mg/dL (high) | High |
| 2026-06-29 | Creatinine | 2.4 mg/dL (high) | High |
| 2026-06-29 | eGFR | 30 mL/min/1.73 m² (low) | Low |
| 2026-06-29 | Urine albumin-creatinine ratio | 360 mg/g (high) | High |
| 2026-10-26 | BUN | 34 mg/dL (high) | High |
| 2026-10-26 | Creatinine | 2.3 mg/dL (high) | High |
| 2026-10-26 | eGFR | 32 mL/min/1.73 m² (low) | Low |
| 2026-10-26 | Intact PTH | 78 pg/mL (high) | High |
| 2026-10-26 | Hemoglobin | 12.8 g/dL (low) | Low |
| 2026-10-26 | Urine albumin-creatinine ratio | 240 mg/g (high) | High |
| 2026-08-10 | BUN | 37 mg/dL (high) | High |
| 2026-08-10 | Creatinine | 2.4 mg/dL (high) | High |
| 2026-08-10 | eGFR | 30 mL/min/1.73 m² (low) | Low |